Floatz logo

Dl-Dobutamine

Vascular Insufficiency Disorder

Explore 1 assets in Vascular Insufficiency Disorder →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Federal University of São Paulo
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Vascular Insufficiency Disorder

AssetSponsorPhaseRating
Dl-Dobutamine (this asset)Federal University of São PauloP2CCC · 53
AdenosineUniversity of UtahN/AD
RegadenosonUniversity of UtahN/AD

Other indications for Dl-Dobutamine

IndicationSponsorPhaseRating
Infectious Disease With Sepsis—P2CCC · 53
Traumatic Brain Injury—P2CCC · 53
Coronary Artery Disorder—Early P1C · 39

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Dl-Dobutamine in Vascular Insufficiency Disorder. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/dl-dobutamine-vascular-insufficiency-disorder

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →